


## Modular mRNA-LNP Platform Inducing Antigen-Specific Immune Tolerance

### 1つのLNPに抗原mRNAと免疫調節薬を共封入 抗原特異的な免疫寛容を実現する次世代プラットフォーム

Integrated Nanotherapeutics (INT) is developing next-generation immune tolerance therapies for autoimmune diseases using its proprietary **Multi-Cargo LNP** platform. The platform **co-delivers disease-relevant antigens and immunomodulators** to promote antigen-specific immune tolerance. Its lead **Type 1 Diabetes** program has generated compelling preclinical data and is advancing toward clinical development.




## Tolerogenic LNP reverse diabetes in NOD mice (T1D model)

NOD mice  
n=4-5/group




--- Buffer  
— INT-101 cohort 1  
— INT-101 cohort 2  
— INT-101 cohort 3  
— INT-101 cohort 4



- Treatment initiated after disease onset; temporary insulin for ~14 days
- 100% remission for the duration of the study (70 days)
- Demonstrates reversal of disease, not just delay
- Demonstrates increased Tregs (data not shown)

## Platform technology can be applied to multiple indications



Learn more:



Supported by:

